Skip to main content
. Author manuscript; available in PMC: 2020 Mar 3.
Published in final edited form as: Int J STD AIDS. 2018 Jan 16;29(6):603–610. doi: 10.1177/0956462417748859

Table 3.

Odds ratios for virologic failure in patients on first-line treatment for six or more months using logistic regression modelling.

Parameter Univariate model Full multivariate model
OR (95% CI) p-value Adjusted OR (95% CI) p-value
Male gender (ref. women) 1.36 (1.33–1.40) <0.001 1.29 (1.25–1.35) <0.001
Age at ART start (Ref. 15–49 years): < 15 years 2.44 (2.35–2.54) <0.001 2.58 (2.37–2.81) <0.001
Age at ART start (ref. 15–49 years): 50 + years 0.77 (0.75–0.80) <0.001 0.90 (0.87–0.95) <0.001
Duration on ART (ref. 1–5 years): 6–12 months 1.25 (1.21–1.31) <0.001 1.34 (1.29–1.40) <0.001
Duration on ART (1–5 years): 5–10 years 1.15 (1.13–1.18) <0.001 1.28 (1.23–1.34) <0.001
Duration on ART (1–5 years): >10 years 1.19 (1.11–1.27) 0.004 1.62 (1.46–1.80) <0.001
CD4 cell count at ART start (ref. > 100) 1.48 (1.44–1.53) <0.001 1.46 (1.41–1.52) <0.001
Initiated at facility (ref. transferred from another facility) 1.17 (1.14–1.20) <0.001 1.39 (1.33–1.45) <0.001
TB status: TB symptoms (ref. no symptoms) 1.18 (1.02–1.38) 0.031 1.03 (0.84–1.27) 0.767
TB status: On TB treatment (ref. no symptoms) 2.56 (2.25–2.92) <0.001 1.78 (1.48–2.13) <0.001
Prior ART: PEP (ref. no prior exposure to ART) 1.31 (1.01–1.71) 0.041 0.99 (0.64–1.54) 0.961
Prior ART: PMTCT (ref. no prior PMTCT) 0.78 (0.74–0.82) <0.001 0.90 (0.84–0.97) 0.003
Prior ART: Prior ART >30 days (ref. no prior exposure to ART) 1.15 (1.07–1.23) 0.001 1.20 (1.08–1.32) 0.001

ART: antiretroviral therapy; CI: confidence interval; OR: odds ratio; PEP: post-exposure prophylaxis; PMTCT: prevention of mother-to-child transmission.